Innovative gene therapy and molecular research offer promising advancements across several disease domains. Paris-based biotech announced encouraging initial results from a gene therapy targeting incontinence in spinal cord injury patients. University of Cambridge researchers identified hyperactive transposases via protein language models, opening avenues for gene editing tools. Multiple studies elucidate novel molecular regulators implicated in cancer metabolism and glioma progression, highlighting targets such as Cathepsin S and P2X7 receptor. Collectively, these advances pave the way for novel treatments addressing complex neurological and oncological conditions.